Recently, it was reported that de novo expression of CD163 by activated microglia/macrophages and CD163+-infiltrating monocytes occurs in both hemorrhagic and non-hemorrhagic brain lesions in patients, highlighting the possibility of targeting CD163-dependent functions for the treatment of both types of lesion [50]. Here, CD163 is linked to hemorrhage.